Study published in Viruses shows superior response with PharmaJet Tropis over electroporation

Bernelin-Cottet et al published a study that demonstrates the delivery of a DNA-based swine influenza vaccine with the PharmaJet Tropis Needle-free Jet Injector resulted in an increased cellular uptake as compared with administration via needle and syringe followed by electroporation. Importantly, administration by Tropis resulted in a non-inferior immune response, a more efficient cell uptake, and an equal potency to elicit an anti-Neuraminidase IgG response.

PharmaJet presents latest Research Results at World Vaccine Congress

GOLDEN, Colo. — May 7, 2019 — PharmaJet®, the maker of innovative, needle-free injection technology, today shared that their latest research results were presented at the World Vaccine Congress on April 16, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effective-ness with Needle-free Delivery, was presented by Dr. Marilyn Dysart, Clinical Affairs Manager at PharmaJet, Inc.

PharmaJet to present latest Research Results at World Vaccine & Immunotherapy Congress

GOLDEN, Colo. — November 27, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced plans to present their latest re-search results at the World Vaccine & Immunotherapy Congress on November 29 at the Loews Coronado Bay Resort in San Diego, California. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.

PharmaJet receives Frost & Sullivan Best Practices Award

Immunization coverage is critical to eradicating potentially deadly diseases while reducing the burden of disease. Safe, cost-effective, and patient-friendly injectable drug delivery systems play a crucial role in the success of global vaccination programs. PharmaJet leverages innovative jet injection technology to offer a needle-free, accurate, and more comfortable method of vaccine delivery. With unparalleled ease-of-use…

PharmaJet and Mundipharma partner to expand access to needle-free technology in emerging markets

SINGAPORE — July 25, 2018 — PharmaJet® the maker of innovative, needle-free injection technology, and Mundipharma, today announced an exclusive partnership for the multinational healthcare organization to market and distribute PharmaJet's Tropis® and Stratis® needle-free devices across more than 120 markets worldwide. Tropis® (ID) and Stratis® (IM/SC) devices are both optimized for vaccine immunizations.

PharmaJet to present latest Research Results at World Vaccine Congress

GOLDEN, Colo. — March 27, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced plans to present their latest research results at the World Vaccine Congress on April 5, in Washington DC at the Renaissance Washington DC Downtown Hotel. The presentation, entitled Expanding Vaccine Effectiveness with Needle-free Delivery, will be presented by Dr. Erin Spiegel, Director of Scientific Affairs at PharmaJet, Inc.

Phase 1 clinical trial for Hantavirus vaccines yields positive interim results

GOLDEN, Colo. — March 13, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the reporting of positive interim results from the Phase 1 clinical trial conducted by the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The clinical trial is evaluating two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS), using the PharmaJet Stratis® needle-free injection system.